Neisseria meningitidis composition and methods thereof

US9724402B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9724402-B2
Application numberUS-201615237005-A
CountryUS
Kind codeB2
Filing dateAug 15, 2016
Priority dateMar 9, 2012
Publication dateAug 8, 2017
Grant dateAug 8, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

First claim

Opening claim text (preview).

What is claimed is: 1. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence set forth as SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 15. 2. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence set forth as SEQ ID NO: 68, wherein an N-terminal cysteine at position 1 is substituted, as compared to SEQ ID NO: 15. 3. The polypeptide according to claim 1 , wherein the polypeptide is immunogenic. 4. The polypeptide according to claim 1 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry. 5. The isolated polypeptide according to claim 1 , wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 68. 6. The isolated polypeptide according to claim 5 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 69. 7. The isolated polypeptide according to claim 1 wherein the amino acid sequence consists of the sequence set forth as SEQ ID NO: 64. 8. The isolated polypeptide according to claim 7 , wherein the polypeptide is encoded by the nucleic acid sequence SEQ ID NO: 63. 9. An immunogenic composition comprising the polypeptide as in any of claims 1 , 3 , 4 , 5 , 6 , 7 , and 6 . 10. The composition according to claim 9 , further comprising an adjuvant.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9724402B2 cover?
In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71 in another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningoco…
Who is the assignee on this patent?
Pfizer
What technology area does this patent fall under?
Primary CPC classification C07K14/22. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).